Cymabay Therapeutics Inc - ESG Rating & Company Profile powered by AI
This webpage is a zero-cost Sustainability analysis for Cymabay Therapeutics Inc. The assessment of Cymabay Therapeutics Inc was prepared by All Street Sevva using proprietary AI. Full ESG assessment of Cymabay Therapeutics Inc can be reached by signing in.
Cymabay Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.2; made up of an environmental score of 5.3, social score of 3.2 and governance score of 4.0.
4.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 951 | Purple Biotech Ltd | 4.3 | High |
| 951 | Vectura Group Services Ltd | 4.3 | High |
| 969 | Cymabay Therapeutics Inc | 4.2 | High |
| 969 | Botanix Pharmaceuticals Ltd | 4.2 | High |
| 969 | Arvinas Inc | 4.2 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Cymabay Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Cymabay Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Cymabay Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Cymabay Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Cymabay Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Cymabay Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Cymabay Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Cymabay Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Cymabay Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Cymabay Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Cymabay Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Cymabay Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Cymabay Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Cymabay Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Cymabay Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Cymabay Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Cymabay Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Cymabay Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.